Long-acting muscarinic antagonist

/Tag:Long-acting muscarinic antagonist

Abstract Number: 128

PREVALENCE AND PREDICTORS OF SUBOPTIMAL PIFR ACROSS GOLD STAGES: ANALYSES FROM THE REVEFENACIN PHASE 3 PROGRAM

Background: Many patients with chronic obstructive pulmonary disease (COPD) have suboptimal peak inspiratory flow rate (sPIFR) because of lung hyperinflation, hypoxemia, and muscle wasting, preventing effective use of dry powder inhalers commonly used to treat [...]

By | 2019-03-11T14:18:46+00:00 March 11th, 2019|Hospital Medicine 2019, Other, Research|Comments Off on PREVALENCE AND PREDICTORS OF SUBOPTIMAL PIFR ACROSS GOLD STAGES: ANALYSES FROM THE REVEFENACIN PHASE 3 PROGRAM
Read More

Abstract Number: 127

EFFICACY AND SAFETY OF REVEFENACIN IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS NOT AGE DEPENDENT: A POST HOC SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS

Background: Revefenacin (REV), a once-daily, long-acting muscarinic antagonist for nebulized inhalation, was recently approved for maintenance treatment of chronic obstructive pulmonary disease (COPD). We present post hoc efficacy and safety data from three phase 3 [...]

By | 2019-03-11T14:18:44+00:00 March 11th, 2019|Hospital Medicine 2019, Other, Research|Comments Off on EFFICACY AND SAFETY OF REVEFENACIN IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS NOT AGE DEPENDENT: A POST HOC SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS
Read More